Editor: Caleb Acquah (PhD)

GFI | GLOBAL REGULATORY WATCH

The FDA has proposed making GRAS notification mandatory. The immediate change is regulatory visibility. The larger question is what happens to ingredient innovation when that visibility becomes part of the cost of entering the U.S. market.

Key Takeaways

• FDA proposed mandatory notification for GRAS uses on August 11, 2026. Comments close December 9, 2026, and the rule is not yet final.
• It is notification, not premarket approval. Companies could market an ingredient once FDA files their notice, while review continues.
• Ingredients already on the market would get a one-year streamlined submission window, closing six months before the 18-month compliance deadline.
• Regulatory evidence could become part of product development, favouring well-capitalized firms and raising supplier documentation expectations.
• FDA capacity is the central implementation risk. The agency expects about 2,400 streamlined human-food submissions and proposes reviews of up to 360 days.
• The U.S., Canada and the EU increasingly reflect regulatory convergence without regulatory harmonization.

The Gap FDA Wants to Close

Under the Federal Food, Drug, and Cosmetic Act, substances added to food are food additives requiring premarket approval unless an exemption applies. The most important exemption covers uses generally recognized among qualified experts as safe. GRAS uses must still meet the food additive safety standard: a reasonable certainty of no harm under the intended conditions of use [2].

What sets the U.S. apart is procedure. Companies can reach independent GRAS conclusions and market ingredients without telling FDA. Because notification has been voluntary, the agency does not necessarily know every substance entering the food supply this way. A widely cited 2011 analysis estimated that roughly 1,000 substances had been marketed on undisclosed GRAS conclusions [3].

As precision fermentation, engineered microorganisms and new processing technologies expand the ingredient pipeline, that blind spot has become harder to defend.

What the Proposal Would Do

Anyone introducing a substance into interstate commerce under GRAS would have to notify FDA and provide the basis for that conclusion [1]. Exceptions include uses already covered by an FDA “no questions” letter or affirmed as GRAS by regulation.

Crucially, this is notification, not approval. Once FDA files a notice, the company could market the substance while review continues. Failure to notify would become a factor in how FDA prioritizes substances for post-market review [1].

For ingredients already on the market, a streamlined pathway would require only the substance’s identity, conditions of use and evidence of prior interstate commerce. FDA would place these on a public list, but listing would not mean the agency had reviewed or endorsed the GRAS conclusion. FDA could later demand a full notice or food additive petition.

If finalized as proposed, the rule would take effect 60 days after publication, with an 18-month compliance period. The streamlined window would last one year, closing six months before that deadline [1]. FDA estimates annualized costs of about $10.5 million to $11.7 million, with upper bounds near $28 million.

Regulatory Evidence Becomes Part of the Product

Large ingredient companies with toxicology and regulatory teams can absorb the work. For smaller biotechnology and precision-fermentation startups, the economics look different. Identity and specifications, manufacturing controls, exposure estimates and toxicological evidence would need to be built alongside R&D rather than assembled just before launch.

That rewards companies that integrate regulatory strategy early and could raise barriers for thinly capitalized innovators. The real question is not whether regulation affects innovation, but which kinds of innovation become easier to commercialize.

Suppliers Will Feel the Pressure First

Manufacturers are likely to ask ingredient suppliers harder questions. Has a GRAS notice been filed? Which conditions of use does it cover? Does the commercial manufacturing process match the one described in the safety dossier? Sophisticated supplier-qualification programs already ask these questions. A mandatory, publicly verifiable filing system makes them harder to treat as optional.

A richer public inventory also becomes competitive intelligence. Tracking filings could give investors, researchers and competitors earlier signals of where ingredient innovation is heading, particularly in fermentation-derived proteins, fats, sweeteners and functional compounds.

Regulatory Convergence Without Regulatory Harmonization

The proposal fits a pattern GFI has been tracking: regulatory convergence without regulatory harmonization. Canada requires premarket assessment of novel foods and new food additives before sale [7]. The EU requires novel food authorization, with scientific risk assessment by EFSA where appropriate [8].

The systems remain fundamentally different, but their direction is similar: regulators want visibility into novel substances entering increasingly complex food systems. A fermentation-derived ingredient could face a U.S. GRAS notice, a Canadian novel food assessment and EU authorization, each demanding overlapping but non-identical evidence. Companies that design safety programs for multiple jurisdictions from the start will hold an advantage.

Capacity Is the Unresolved Question

Greater visibility does not automatically mean faster or better regulation. FDA would conduct a 45-day filing evaluation, then generally respond within 180 days, extendable to 360 [1]. It anticipates around 2,418 streamlined human-food submissions [4].

Industry groups have focused on exactly this. FMI supports modernization but argues durable reform requires congressional authority, adequate resources and a national standard that avoids a state-by-state patchwork [5]. The American Feed Industry Association stressed that FDA needs the capacity to keep reviews timely [6].

The significance of GRAS reform goes beyond closing a long-criticized gap. It could change how ingredient companies approach innovation itself, making the regulatory evidence package part of the product. The U.S. would still not have the same system as Canada or the European Union. But the next generation of ingredient competition may depend not only on who can discover and manufacture a new molecule, but on who can build the evidence needed to commercialize it across markets.

Related on GFI: The UK Is Building a Regulatory Playbook for the Next Generation of Food Biotechnology and Europe Is Starting to Treat Fermentation as Industrial Infrastructure.

---

Sources

1. U.S. Food and Drug Administration. Substances Generally Recognized as Safe, Proposed Rule. 91 FR 51834. August 11, 2026. Docket FDA-2025-N-3262. Federal Register
2. U.S. Food and Drug Administration. Generally Recognized as Safe (GRAS). Program page, updated August 2026. FDA
3. Neltner TG, Kulkarni NR, Alger HM, et al. Navigating the U.S. Food Additive Regulatory Program. Comprehensive Reviews in Food Science and Food Safety. 2011;10(6):342-368.
4. Food Safety Magazine. FDA’s Proposed Mandatory GRAS Rule: What Food Safety Professionals Need to Know. August 2026. Article
5. FMI, The Food Industry Association. FMI Statement on FDA’s Proposed Rule on GRAS. August 10, 2026. Statement
6. American Feed Industry Association. AFIA Responds to Proposed Changes to the GRAS Framework. August 10, 2026. Statement
7. Health Canada. Pre-market Oversight of Certain Food Products Sold in Canada.
8. European Commission. Novel Food Authorisations.